On November 6, Novartis exhibited Ianalumab, an innovative drug under development in the field of immunity, for the first time at the 9th Expo. Through the “China First Exhibition”, Novartis's research progress in the field of Sjogne syndrome was presented. Gao Rong, head of Novartis Drug Development in China, said that the Expo provided an excellent platform for the company to showcase global innovation achievements, and China is becoming the world's first market for Novartis's breakthrough therapies.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.